Categories
Health

CDC says there’s seemingly hyperlink between uncommon coronary heart irritation in younger folks after Covid shot

A CDC safety group said there was a “likely link” between rare heart inflammation in adolescents and young adults, mostly after they received their second Covid-19 vaccine, citing the latest available data.

There have been more than 1,200 cases of myocarditis or pericarditis, mostly in those under 30 who have the Covid- Vaccine received from Pfizer or Moderna have practices methods exercises.

Myocarditis is the inflammation of the heart muscle while pericarditis is the inflammation of the membrane that surrounds the heart.

“The clinical picture of myocarditis cases after vaccination was variable and most often appeared within a week of the second dose, with chest pain being the most common,” said Dr. Grace Lee, Chair of the Committee’s Security Group. CDC officials are collecting more data to fully understand the potential risks, how to deal with them and if there are any long-term issues, she said.

Zoom In Icon Arrows pointing outwards

The agency said 267 cases of myocarditis or pericarditis were reported after receiving one dose of the mRNA vaccines and 827 cases after two doses by June 11. There are 132 additional cases where the number of doses received is unknown, the CDC said.

The agency announced that around 300 million shots had been administered by June 11.

“This is still a rare occurrence,” said Dr. Tom Shimabukuro at the meeting. For both vaccines combined, there were 12.6 cases of heart inflammation per million doses. Cases were more common among Moderna vaccine recipients at 19.8 cases per million than eight cases per million at Pfizer, he said.

Men under 30 make up the bulk of cases, the CDC said, and most cases appear to be mild. Of the 295 people who developed the disease and were discharged, 79% made a full recovery, according to the presentation. Nine people were hospitalized, according to the agency, two of them in the intensive care unit.

CDC officials said the benefits of the Covid vaccine still outweigh the risks.

Cases in younger people are increasing as older people are vaccinated at higher rates. The US vaccinated 177.6 million people with at least one dose, according to the CDC, that’s about 53% of the population. Only 13.6% of 18- to 24-year-olds in the United States received at least one dose of vaccine, compared with 26% of people ages 50 to 64, the data shows.

While hospitalization rates have decreased in older age groups, they have barely moved in adolescents and young adults, said Dr. Megan Wallace from the CDC.

“Teenagers and young adults make up a larger proportion of the total cases, 33% of the cases reported in May were people ages 12-29, compared with 28% last December,” she said. Since the pandemic began, 2,767 people aged 12 to 29 have died of Covid, she said, noting that 316 of these deaths had occurred since April 1.

The CDC is coordinating its investigation with the Food and Drug Administration, which last month approved the Pfizer BioNTech vaccine for adolescents ages 12-15. Symptoms like chest pain and shortness of breath usually develop within a week of receiving the vaccination, with most developing within four days, the agency said.

This is a developing story. Please check again for updates.

CNBC’s Rich Mendez contributed to this article.

Correction: Most of the cases of people who had myocarditis occurred in people under the age of 30. In a previous version, the age was incorrectly stated. The number of cases per million doses administered was 12.6. In an earlier version, the number was incorrectly specified.

Categories
Health

Moderna says it hasn’t discovered a hyperlink between its shot and coronary heart irritation

A healthcare worker stops during the coronavirus pandemic (COVID-19) in New York on Jan.

Facebook Facebook logo Sign up on Facebook to connect with Mike Segar Reuters

Moderna has not found a link between its Covid-19 vaccine and the rare heart inflammation cases reported in young people who received the vaccination, the company said on Friday.

The Massachusetts-based biotech said it reached the conclusion after “carefully reviewing the safety data previously available for the Moderna COVID-19 vaccine for cases of myocarditis and / or pericarditis”.

“The company will continue to monitor these reports closely and is actively working with public health and regulators to further evaluate this issue,” said a statement.

A spokesman for the Centers for Disease Control and Prevention did not immediately respond to a request for comment.

A CDC advisory body is organizing on 18.

A CDC official said Thursday that by May 31, the agency had received reports of 275 cases of myocarditis or pericarditis in this age group, up from the 10 to 102 expected cases. The condition includes inflammation of the heart muscle or the lining around it.

“We clearly have an imbalance,” said Dr. Tom Shimabukuro of the CDC’s Immunization Safety Office on Thursday at a meeting of the FDA’s Advisory Committee on Vaccines and Related Biological Products. The group met to discuss safety issues related to the use of Covid-19 vaccines in children 6 months and older.

The CDC’s vaccine safety group said last month it is studying heart infections in “relatively few” people who have received Covid vaccinations. Officials say they still don’t know if the condition is really related to the vaccines.

Some of the reported cases could be something other than myocarditis or pericarditis upon further investigation, Shimabukuro said Thursday.

Men make up the majority of reported cases and most cases appear to be mild, officials say. Of the 270 people who developed the disease and were discharged, 81% made a full recovery, according to a CDC presentation at Thursday’s meeting. By May 31, 15 people had been hospitalized, three of them in intensive care, the agency said.

Although no link has been found between the vaccines and the disease, health experts say side effects occur rarely once a vaccine or drug is administered to the general population. The US has distributed millions of Covid vaccines which have helped contain new cases and hospital stays across the country.

Categories
Business

Class and Covid: A Key Hyperlink in Layoffs Worldwide

In the United States and many other countries, lower-income, lower-educated adults are harder hit economically by the coronavirus pandemic.

The relationship between class and Covid-19 isn’t inevitable, however: it doesn’t exist in some of the most egalitarian societies in Europe and Asia, according to a new Gallup global survey conducted from July 2020 to March 2021.

Globally, 41 percent of workers in the poorest 20 percent of their county’s income distribution said they had lost their job or business due to the pandemic, compared with 23 percent of workers in the richest 20 percent. This job loss gap is similar between those with a college degree (16 percent who lost a job or company) and those without (35 percent).

The gap in economic vulnerability is closely related to the prevailing income inequality that has accompanied the pandemic. In the economically most egalitarian countries (as measured by the Gini coefficient for household income), workers with lower incomes and lower levels of education were protected from mass unemployment, including through national measures to prevent job loss.

Public health experts have long understood that socioeconomic status is closely related to health outcomes and susceptibility to infectious diseases. Some countries – including the US, England and France – have found that Covid-19 has resulted in higher deaths in low-income communities, as well as blacks and some ethnic minorities.

Most of these gaps appear to be due to work-related exposures rather than non-compliance with safety guidelines. Black people in the United States are more likely than whites to report social distancing and mask use, but at the start of the pandemic, they were about 30 percent more likely to work in jobs that required close physical proximity. This is evident from research to be published in the Annals of the American Academy of Political and Social Science.

The earnings gap is even wider: workers in the bottom third of the income distribution were four times more likely than workers in the top 10 percent to be in a job that required close physical proximity. With the exception of doctors and a few other professions, highly skilled workers rarely need to be in direct contact with other people.

The overexposure of low-income workers to personal and personal work has created a twofold risk for the less affluent: increased threats of physical and economic harm. For example, in the United States, the unemployment rate of food preparation and service workers rose from 5.5 percent to 19.6 percent from 2019 to 2020 as people stopped eating out.

Around the world, lockdowns and social distancing have destroyed lower-income jobs that require less education. In 103 of 117 countries in Gallup’s World Poll data, workers in the bottom quintile of household income distribution had significantly higher job loss rates than those in the top. University graduates fared significantly better than graduates with less than 16 years of education in 97 out of 118 countries and territories.

Updated

May 3, 2021, 6:22 p.m. ET

Ungraduate workers in low-income countries fared worst, although they tended to live in areas with much lower Covid-19 fatalities during the survey period than in high-income countries in Europe and North America . More than two in three non-college workers lost their jobs or business as a result of Covid-19 in the Philippines and Kenya, even though the per capita death rate was 7 percent and 2 percent of the United States, respectively.

More than half of those without a university degree lost their jobs in Zimbabwe, Thailand, Peru and India. The rate of job or business loss among workers with a university degree in these countries was at least 10 percentage points lower.

While the economic damage has generally been worse in low-income countries, the United States is distinguished among high-income democracies by high job losses and a wide gap between those with and without college degrees. Of the 31 OECD member countries with data, the United States had the third largest gap in job loss between college graduates and non-holders, after Chile and Israel (eight percentage points).

Chile, Israel and the United States also share the difference that they have high levels of income inequality. More egalitarian countries – including France, Switzerland, Denmark, Sweden, Norway and Germany – kept job losses low overall and did not see a significant gap in job loss rates between those with and without university degrees.

Globally, pre-pandemic income inequality predicted significantly higher job losses and a greater role for socio-economic status in shaping those job losses. The effect of inequality remains significant even after controlling for the cumulative per capita deaths from Covid-19 and the rigor of government policies to suppress disease and other factors that vary from country to country, as measured by Oxford University scientists.

More egalitarian countries tend to have more trusting populations, research shows, and create conditions that seem to lead to cooperation and effective collective action.

It is possible that elected officials in more egalitarian countries are more likely to develop measures to protect workers from dismissal – as is the case in Denmark, the Netherlands and New Zealand, which are in the lower quintile of global inequality measures, as well as Ireland, Australia and Great Britain, which are in the second lowest quintile in inequality.

These guidelines directed income support to companies affected by the pandemic in order to maintain their workforce. Other more egalitarian countries – such as France, Germany and Switzerland – have used and expanded existing employer subsidy programs to keep workers loyal to employers.

No such guidelines were issued in Chile or Israel while the US government launched the Paycheck Protection Program. This program shared features with successful European policies, but came too late to prevent mass layoffs, as Federal Reserve economists have noted, with too many administrative and eligible complications.

Despite these restrictions, according to an analysis by US Treasury Department economists, the layoffs in the US would have been drastically worse without them. The federal government has increased spending significantly in other ways to reduce the damage done to the laid-offs, such as subsidized unemployment insurance and direct payments to low- and middle-income households.

But there’s a good reason why it’s best not to get laid off at all: Previous recessions have shown that millions of laid-off workers will never return to their employers.

In addition, recent data from Gallup’s Great Job Survey shows that people laid off and rehired as a result of the pandemic saw sharp drops in job satisfaction and continued to struggle to meet monthly expenses. Globally and in the US, the world survey shows that those laid off as a result of the pandemic were significantly more likely to see a decline in their standard of living compared to the previous year.

Jonathan Rothwell is a Principal Economist at Gallup, a resident senior fellow at the Brookings Institution, and a visiting scholar at the George Washington University Institute of Public Policy. He is the author of “A Republic of Equals: A Manifesto for a Just Society”. You can follow him on Twitter at @jtrothwell.

Categories
World News

U.Okay. says under-30s ought to get a non-AstraZeneca possibility; E.U. finds a ‘potential hyperlink’ to uncommon clots.

The UK said Wednesday that it would offer alternatives to the AstraZeneca vaccine for adults under 30 as European regulators identified a “possible link” with rare blood clots, a setback for the world’s most widely used vaccine and a blow for the 100+ Described countries relying on it to save lives amid a global surge in coronavirus cases.

The European regulator, the European Medicines Agency, has no longer advised restricting the use of the vaccine in the 27 countries of the European Union, stating that it is up to national authorities to decide who should receive which vaccine.

Until the announcement, the UK had never let up in the use of the vaccine, making it a holdover in Europe, although many countries discovered unusual, sometimes fatal, blood clots in some recipients. However, there is evidence that very few Britons were also affected, forcing the country to reduce the use of a vaccine, which is the backbone of its world’s best immunization program, among younger people.

Concerns about the blood clots have threatened the pace of vaccination well beyond Europe. At least 111 countries of different incomes have administered doses of AstraZeneca’s shot, making it the most powerful weapon of international aid groups in the fight against the death toll in AstraZeneca Countries with a shortage of vaccines.

Both UK and European regulators said it was possible the clots were linked to the vaccine but that more research was needed. The European regulators described the cases as a serious but “very rare” side effect.

According to official information, the European regulatory authorities had received reports of 222 cases of the rare blood clotting problem in Great Britain and the European Economic Area with 30 countries (European Union plus Iceland, Norway and Liechtenstein) by Sunday. They said that about 34 million people in those countries had received the AstraZeneca vaccine and that the coagulation problems occurred at a rate of about 1 in 100,000 recipients. The condition can be treated.

European regulators said they had carried out detailed reviews of 86 cases by March 22, of which 18 were fatal.

The agency reiterated that the general benefits of the vaccine still outweighed the risks, but urged health professionals and recipients of the shot to be careful about symptoms such as shortness of breath, chest pain, or leg swelling.

Many European countries have restricted the use of the vaccine in younger people as some scientists believe they are at greater risk of developing the rare blood clots. You also have a lower risk of developing severe Covid-19, which raises the safety bar for any vaccine given to younger people.

However, the regulator said it had not concluded that age or gender posed a specific risk and would investigate the issue further.

“This case clearly shows one of the challenges posed by large-scale vaccination campaigns,” said Emer Cooke, head of the agency, in a press conference Wednesday. “When millions of people receive these vaccines, very rare events that were not identified during clinical trials can occur.”

“The risk of mortality from Covid is much greater than the risk of mortality from the side effects,” added Ms. Cooke.

No other vaccine has sparked as much controversy as the shot by the British-Swedish company who used the Block Spats on supply cuts, its effectiveness and ultimately on rare but sometimes fatal blood clots that have been reported in some recipients.

These concerns prompted several European countries to first restrict the use of AstraZeneca in older age groups and then suspend it on reports of blood clots, only to reintroduce it last month after the European Medicines Agency issued a preliminary opinion on the vaccine’s benefits outweighing the risks .

Because doctors reported a higher incidence of severe blood clots in younger people, some countries decided to stop giving the shot to anyone under the age of 55.

Europe’s concerns about the vaccine’s side effects are also likely to threaten global vaccination efforts, with much of the developing world relying on the AstraZeneca vaccine to help fight the pandemic. The shot is the cornerstone of Covax, a program designed to make vaccine access more equitable around the world.

The vaccine appeared to trigger an immune response in which antibodies bind to platelets and activate them, German doctors and the European Medicines Agency have said. These platelets, in turn, caused dangerous clots to form in certain parts of the body, including veins that drain blood from the brain, leading in some cases to a rare type of stroke.

Doctors have said why the antibodies develop in these people is not known. Some component of the vaccine or an excessive immune response – or both – could be the cause, they said.

There is no known disease that makes patients more susceptible to this coagulation disorder after vaccination, according to the European regulatory authorities.

Categories
Business

EU medicines regulator finds doable hyperlink between AstraZeneca Covid vaccine and blood clots

Syringes are filled with Astrazeneca’s vaccine in the pharmacy.

Christopher Neundorf | Image Alliance | Getty Images

LONDON – Europe’s Medicines Agency announced on Wednesday a possible link between the coronavirus vaccine developed by AstraZeneca and Oxford University and rare blood clotting problems in adults who received the shot.

It comes after a review of all currently available evidence in extremely rare cases of unusual blood clots in some vaccinated individuals.

Emer Cooke, executive director of the European Medicines Agency, said in a televised press conference that the regulator’s safety committee “has confirmed that the overall benefits of the AstraZeneca vaccine in preventing Covid-19 outweigh the risks of side effects.”

“A plausible explanation for these rare side events is an immune response to the vaccine that is similar to that seen in heparin-treated patients,” said Cooke, noting that it was heparin-induced thrombocytopenia.

The EMA has commissioned further research to investigate the link between the vaccine and blood clots, and said its safety committee had concluded that unusual blood clots with low platelets should be listed as “very rare” side effects of the shot. It also drew the public’s attention to other possible side effects that are flagged as adverse drug reactions on the product information of the vaccine.

The European Medicines Agency said it was “of great importance” that health professionals and those receiving the Oxford-AstraZeneca vaccine are aware of these risks and look out for possible symptoms, typically in the first two weeks after vaccination occur.

“These include, for example, shortness of breath, chest pain, swelling in the leg, persistent abdominal pain, neurological symptoms such as severe or persistent headaches or blurred vision and skin bruises beyond the injection site,” said Dr. Sabine Straus, chair of EMA’s security committee, said at the same press conference.

AstraZeneca’s shares fell nearly 1% during afternoon trading in London.

The Oxford-AstraZeneca shot has been followed by safety concerns in recent weeks, and several European countries temporarily stopped using the vaccine last month.

The EMA said on March 31 that it had found the shot to be safe and effective, but added that it could not rule out the possibility of a causal link between the vaccine and coagulation events, so the investigation will continue.

The World Health Organization, the UK Medicines Agency and the International Society on Thrombosis and Hemostasis have all stated that the benefits of administering the Oxford-AstraZeneca shot far outweigh the risks.

AstraZeneca previously said that its studies didn’t find a higher risk of blood clots as a result of its vaccine.

Most countries have since resumed the use of the shot, but many have suspended vaccinations for certain age groups.

A senior European Medicines Agency official said Tuesday that there was a clear “link” between the Oxford-AstraZeneca vaccine and very rare blood clots in the brain, although the direct cause was not yet known.

In an interview with the Italian newspaper Il Messaggero published on Tuesday, Marco Cavaleri, chairman of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say that there is a link to the vaccine, but we are still me don’t know what is causing this reaction. “

The EMA then denied in a statement to Agence France-Presse that it had made a connection between the Oxford-AstraZeneca shot and rare blood clots.

UK vaccine study in children paused

The drug and health products regulator, which approved the Oxford-AstraZeneca vaccine for use in the UK, examined the data after a handful of reports – in both the UK and continental Europe – of serious but rare blood clots, some of which were fatal .

A UK study of the Oxford AstraZeneca vaccine in children has already been paused while the drug agency investigated a possible link between the shot and the bleeding disorders, particularly cases of blood clots in veins in the brain known as cerebral venous sinus thrombosis (CVST) as well Thrombocytopenia (low levels of platelets in the blood that help blood to clot).

The UK government noted that as of March 24th inclusive, there were 22 reports of CVST and 8 reports of other low platelet thrombosis events totaling 18.1 million doses of the AstraZeneca vaccine (one shot with two doses). given up to this date.

People are waiting in a vaccination center in Cologne on April 5, 2021.

Marius Becker | Image Alliance | Getty Images

“We need to know more about those affected and understand exactly how the diseases came about while many other questions remain open,” said Adam Finn, professor of pediatrics at Bristol University, UK, ahead of the announcement on Wednesday.

“There are some things that are very clear, however. The first is that these cases are indeed very rare. The second is that the vaccines available and used in the UK are very effective in preventing COVID,” said Finn.

“In short, if you are currently offered a dose of Oxford AstraZeneca vaccine, your chances of staying alive and staying healthy will go up if you take the vaccine and go down if you don’t.”

– CNBC’s Holly Ellyatt contributed to this report.

Categories
Business

Chipotle will hyperlink govt compensation to environmental and variety objectives

Brian Niccol, CEO of Chipotle Mexican Grill

Adam Jeffery | CNBC

Chipotle Mexican Grill said Thursday that executive compensation will now be tied to achieving goals related to the company’s environmental and diversity goals.

The burrito chain is following in the footsteps of Starbucks and McDonald’s, both of which recently announced that performance for racial and gender diversity goals will impact executive compensation plans. Individual investors and large asset managers like BlackRock are increasingly choosing stocks with strong environmental, social and corporate governance in mind, pushing companies to make changes to become a more attractive investment.

“I think the increased focus on ESG performance and investor feedback was definitely the reason we decided to bring this to the public,” said Laurie Schalow, who is chief corporate affairs officer and food safety officer is responsible for sustainability and ESG reporting for Chipotle.

Starting this year, 10% of annual incentives for Chipotle executives will be tied to their progress toward corporate goals.

“It is very important that we are transparent and accountable. We can say a lot of words, but we want to make sure that we have the measures to support this,” said Schalow.

These goals include increasing the pounds of organic, local, or regeneratively grown or cultured foods from the previous year. Last year, Chipotle produced £ 31 million of local products under this umbrella, and a target of £ 37 million has been set by the end of 2021.

The company plans to publish its carbon footprint including all indirect emissions along its value chain by the end of the year faster than the expected publication date in 2025. Schalow announced that the company will announce new sustainability goals based on these findings when the report is released.

Chipotle is also committed to upholding both racial and gender pay equality and promoting more women and people of color above the restaurant level. A training academy has been established with online courses teaching a wide range of skills, from conflict resolution to goal setting, with the aim of helping employees of different backgrounds climb the corporate ladder. As of December 31, the company had almost 88,000 employees.

Chipotle’s shares are up 91% over the past 12 months, equating to a market value of $ 39.6 billion.